Table 3.
Summary of TmaxROS and ET50NET Changes Under LA Impact
| LA | LA-Concentration [mmol/L] | TmaxROS [min] Median ± SD |
ET50NET [min] Median ± SD |
|---|---|---|---|
| Bupivacaine | 0 | 115.5 ± 46.0 | 320.4 ± 47.5 |
| 0.03 | 101.6 ± 12.2 | 349.7 ± 31.4 | |
| 0.09 | 81.47 ± 21.64 | 338.6 ± 35.6 | |
| 0.16 | 88.5 ± 34.4 | 296.2 ± 34.0 | |
| 0.32 | 164.4 ± 34.8 | 314.6 ± 12.4 | |
| 0.63 | 70.5 ± 16.9 | 319.3 ± 39.0 | |
| 0.95 | 229.8 ± 37.4 | ||
| 1.58 | 107.3 ± 29.3 | ||
| 3.2 | 83.0 ± 6.11 | ||
| Lidocaine | 0 | 115.5 ± 46.0 | |
| 0.007 | 110.5 ± 24.8 | 355.8 ± 10.2 | |
| 0.14 | 106.6 ± 6.1 | 356.3 ± 5.81 | |
| 0.71 | 102.5 ± 21.5 | 428.9 ± 13.8 | |
| 1.42 | 100.9 ± 17.2 | 392.0 ± 50.7 | |
| 3.55 | 143.7 ± 38.0 | 343.9 ± 26.9 | |
| 7.1 | 101.7 ± 35.7 | 240.7 ± 23.7 | |
| 14.21 | 49.0 ± 18.8 |